Many people regain some or most of the weight they lost after stopping semaglutide
Clinical studies, including the STEP 1 extension trial, have demonstrated that patients who discontinue GLP-1 receptor agonists often regain a significant portion of lost weightsometimes two-thirds or morewithin one year of stopping treatment
Some versions may have a short-term stability Best Practices for Managing BUD and Expiration Check the pharmacy label for BUD and storage instructions
Insurance coverage creates another decision point
Is it the same as the brand name version?", CBC News website , archived from the original on 20 May 2026 "Australian Product Information: Ozempic (semaglutide) solution for injection" (PDF), Therapeutic Goods Administration website , 30 October 2020, archived from the original (PDF) on 8 June 2025 "Assessment report: Ozempic" (PDF), European Medicines Agency website , 11 November 2021, archived from the original (PDF) on 6 February 2025 1 2 "Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs"
